Motor Seizures Confer Overall Survival Benefit in WHO Grade 2 Glioma
| Autor: | Sam Fairclough, Ryan Mathew, John Goodden, Paul Chumas, Melissa Maguire |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Neuro-Oncology. 24:iv11-iv11 |
| ISSN: | 1523-5866 1522-8517 |
| DOI: | 10.1093/neuonc/noac200.051 |
| Popis: | AIMS The prevalence of epilepsy in WHO grade 2 glioma is high, with seizures often being the presenting symptom. We explore the epidemiology of seizures in this patient population in a regional neurosurgical centre. METHOD Electronic health records of patients with histologically-proven WHO grade 2 glioma (n=227) were reviewed with data collected including patient demographics, epilepsy prevalence and seizure semiology. Relationships between epilepsy and overall survival were calculated using a Cox proportional hazards model in the statistical software “R,” controlling for all other variables – including histological diagnosis. RESULTS Overall, 196/227 (86.3%) patients were diagnosed with epilepsy - either at presentation (179/196, 91.3%), or during the course of their disease (17/196, 8.7%) . Mean follow-up was 7.0 years. Diffuse astrocytoma histology was associated with reduced overall 10-year survival (HR 4.68, p CONCLUSION Most WHO Grade 2 glioma patients experience focal seizures, though generalised tonic-clonic seizures are common. Motor seizure activity is a frequent feature in WHO Grade 2 glioma and may confer a survival benefit, when compared to patients that have primarily non-motor seizure activity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|